Development of StaphVAX™, a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials

Vaccine

Volumn 22, Issue 7, 2004, Pages 880-887

  Fattom, Ali I ^a   Horwith, Gary ^a   Fuller, Steve ^a   Propst, Myra ^a   Naso, Robert ^a  

^a Nabi Biopharmaceuticals   (United States)

Author keywords

Conjugate vaccine; Polysaccharide; Staphylococcus

Indexed keywords

ALTASTAPH; ANTIBIOTIC AGENT; BACTERIAL VACCINE; IMMUNOGLOBULIN G; POLYSACCHARIDE; STAPHVAX; VANCOMYCIN; STAPHYLOCOCCUS VACCINE; VACCINE;

ACTIVE IMMUNIZATION; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERANCE; ERYTHEMA; HEMODIALYSIS; HOSPITAL INFECTION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; LETHAL DOSE; MULTIDRUG RESISTANCE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; TH2 CELL; ANIMAL; IMMUNOLOGY; REVIEW; STAPHYLOCOCCUS INFECTION;

ANIMALS; CLINICAL TRIALS, PHASE III; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 0842346288     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.034     Document Type: Conference Paper

References (45)

1. Pfaller M.A., Jones R.N., Doern G.V., Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42(7):1998;1762-1770.
2. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N.et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):2001;S114-S132.
3. Diekema D.J., Pfaller M.A., Jones R.N. Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America. SENTRY Antimicrobial Surveillance Program, 1997-2000. Int. J. Antimicrob. Agents. 20(6):2002;412-418.
4. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111(9):2003;1265-1273.
5. Brumfitt W, Hamilton-Miller J. The worldwide probem of methicillin-resistant Staphylococcus aureus. Drugs Exp Clin Res 1990;16205-14.
6. Boyce JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus. In: The United States. Infect Control Hospital Epidemol 1990;11639-42.
7. Begley S. Antibiotics the end of miracle drugs? Newsweek 1994;46-51.
8. Naimi T.S., LeDell K.H., Boxrud D.J., Groom A.V., Steward C.D., Johnson S.K.et al. Epidemiology and clonality of community-acquired methicillin- resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin. Infect. Dis. 33(7):2001;990-996.
9. Moore M.R., Perdreau-Remington F., Chambers H.F. Vancomycin treatment failure associated with heterogeneous vancomycin - intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47(4):2003;1262-1266.
10. Grabs A.J., Lord R.S. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med. J. Aust. 176(11):2002;563.
11. Gopal V., Bisno A.L., Silverblatt F.J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. J. Am. Med. Assoc. 236(14):1976;1604-1606.
12. Noble W.C., Virani Z., Cree R.G. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 72(2):1992;195-198.
13. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104(5A):1998;7S-10S.
14. Hiramatsu K., Aritaka N., Hanaki H.et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350(9092):1997;1670-1673. [see comments].
15. CDC. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR 1997;46(27):624-35.
16. CDC. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002;51(26):565-7.
17. Foster TJ. Potential for vaccination against infections caused by S. aureus. Vaccine 1991;9221-7.
18. Wright AE, Douglas SR. An experimental investigationof the role of fluids in connection with phagocytosis. Proc R Soc London 1904;73128-42.
19. Quie PG. Bactericidal function of human polymorphonuclear leukocytes. Pediatrics 1972;50264-70.
20. Rogers DE, Melly MA. Speculation on the immunology of staphylococcal infection. Ann N Y Acad Sci 1965;128274-84.
21. Fattom A.I., Naso R. Staphylococcal vaccines: a realistic dream. Ann. Med. 28(1):1996;43-46.
22. Essawi T., Na'was T., Hawwari A., Wadi S., Doudin A., Fattom A.I. Molecular. Trop. Med. Int. Health. 3(7):1998;576-583.
23. Karakawa WW, Vann WF. Capsular polysaccharides of Staphylococcus aureus. In: Weinstein L, Fields BN, editors. Semin Infect Dis 1982;285-93.
24. Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. Capsular atibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1988;561090-5.
25. Arbeit R.D., Karakawa W.W., Vann W.F., Robbins J.B. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2(2):1984;85-91.
26. Sompolinsky D, Samra D, Karakawa WW, Vann WF, Schneerson R, Malik Z. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. Infect Immun 1985;22828-34.
27. Fattom A, Naawas T, Hawwari A. S. aureus nasal carriage as a risk factor for pneumonia but not bacteremia in shock trauma patients. In: Proceedings of the 95th American Society of Microbiology; 1995.
28. Essawi T., Na'was T., Hawwari A., Wadi S., Doudin A., Fattom A.I. Molecular, antibiogram and serological typing of Staphylococcus aureus isolates recovered from Al-Makased Hospital in East Jerusalem. Trop. Med. Int. Health. 3(7):1998;576-583.
29. Daum R.S., Fattom A., Freese S., Karakawa W. Capsular polysaccharide serotypes of coagulase-positive staphylococci associated with tenosynovitis, osteomyelitis, and other invasive infections in chickens and turkeys: evidence for new capsular types. Avian. Dis. 38(4):1994;762-771.
30. Poutrel B., Boutonnier A., Sutra L., Fournier J.M. Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk. J. Clin. Microbiol. 26(1):1988;38-40.
31. Fournier J.M., Hannon K., Moreau M., Karakawa W.W., Vann W.F. Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. Ann. Inst. Pasteur. Microbiol. 138(5):1987;561-567.
32. Moreau M., Richards J.C., Fournier J.M., Byrd R.A., Karakawa W.W., Vann W.F. Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr. Res. 201(2):1990;285-297.
33. Fattom A., Schneerson R., Szu S.C., Mestecky J., Schiffman G., Bryla D. et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus types 5 and 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect. Immun. 58(7):1990;2367-2374.
34. Robbins JB, Schneerson R. Polysaccharide-protein conjugates. A new generation of vaccines. J Infect Dis 1990;161821-32.
35. Chu C., Schneerson R., Robbins J.B., Rastogi S.C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 40(1):1983;245-256.
36. Fattom A.I., Sarwar J., Ortiz A., Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64(5):1996;1659-1665.
37. Lee J.C., Park J.S., Shepherd S.E., Carey V., Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 65(10):1997;4146-4151.
38. Fattom A., Schneerson R., Watson D.C., Karakawa W.W., Fitzgerald D., Pastan I. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus types 5 and 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61(3):1993;1023-1032.
39. Fattom A.I., Naso R. Staphylococcus aureus vaccination for dialysis patients - an update. Adv. Ren. Replace Ther. 3(4):1996;302-308.
40. Welch P.G., Fattom A., Moore J. Jr., Schneerson R., Shiloach J., Bryla D.A.et al. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J. Am. Soc. Nephrol. 7(2):1996;247-253.
41. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J.et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346(7):2002;491-496.
42. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of immunocompromised host. Clin Microbiol Rev 1998;111-26.
43. Haag-Weber M., Hable M., Schollmeyer P., Hort W., urth S.L. Metabolic response of neutophils to uremia nad dialysis. Kidney Int. 36(Suppl. 27):1989;S293-S298.
44. Nolan C, Beaty H, Bagdade J. Impaired granulocyte bactericidal function in patients with poorly controlled diabetes. Diabetes 1978;127889-94.
45. Schneerson R, Robbins JB, Parke JC, Bell C, Schlesselman JJ, Sutton A, et al. Quantitative and qualitative analysis of serum antibodies elicited in adults by Haemophilus influenzae type B and Pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986;52519-28.